IDRA-21 (7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide) is an ampakine drug and a benzothiadiazine derivative with nootropic properties.
It is “very likely IDRA 21 exerts its behavioral effects by antagonizing AMPA receptor desensitization.”
Ampakines stimulate glutamatergic AMPA receptors therebye enhancing concentration and attention span, making this class of compounds interesting novelties for the treatment of learning disabilities as well as overall cognitive enhancement.
It is surmised that IDRA-21 is a potent cognition-enhancing drug virtually devoid of neurotoxic liability because it acts as a partial negative allosteric modulator of AMPA receptor desensitization.
In preliminary scientific studies, IDRA-21 has shown to significantly increase learning and memory performance.
IDRA-21 was originally used to reverse cognitive deficits caused by scopolamine and alprazolam.
IDRA-21 A Powerful New Nootropic
IDRA21 is a partial modulator of ampa with cognition-enhancing properties in learning and memory applications.
It is assumed to have long term potentiation as a positive allosteric modulator useful for cognitive impairments and recognition memory.
This Certified Reference Material is available for research use only